home / stock / nbrv / nbrv news

NBRV News and Press, Nabriva Therapeutics plc From 11/05/21

Stock Information
Company Name: Nabriva Therapeutics plc
Stock Symbol: NBRV
Market: NASDAQ
Menu
NBRV NBRV Quote NBRV Short NBRV News NBRV Articles NBRV Message Board
Get NBRV Alerts

News, Short Squeeze, Breakout and More Instantly...
NBRV - Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroed...
NBRV - Nabriva Therapeutics reports inducement grant to CMO

Nabriva Therapeutics (NASDAQ:NBRV) granted a non-statutory stock option to purchase 100K shares as an inducement to Christine Guico-Pabia, Nabriva’s newly appointed CMO. The stock option was granted effective Oct.29 with an exercise price of $1.15/share; it has a 10-year...

NBRV - Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021

DUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter fin...

NBRV - Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentati...
NBRV - Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data t...

NBRV - Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock...

NBRV - Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of ...
NBRV - Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 PR Newswire WASHINGTON , Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and s...

NBRV - Nabriva Therapeutics to Present Data at IDWeek 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced data presentati...

NBRV - Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient's Pharmacy Network Program

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered i...
Previous 10 Next 10